🚀 Medial Secures Investment on Shark Tank India - Fueling the Future of Professional Social Networking. 🔥
Login

News on Medial

Exclusive: Peak XV joins Truemeds’ Series C round with $20 Mn

EntrackrEntrackr · 2m ago
Exclusive: Peak XV joins Truemeds’ Series C round with $20 Mn
Medial

Exclusive: Peak XV joins Truemeds’ Series C round with $20 Mn Telehealth platform Truemeds has secured another $20 million or Rs 174.33 crore in its ongoing Series C round from new investor Peak XV Partners. This investment is an extension of the $44 million raised by Truemeds in March this year, led by Accel, which was exclusively reported by Entrackr. The board at Truemeds has allotted 19,737 Series C2 compulsory convertible preference shares at an issue price of Rs 88,331 each to raise the aforementioned sum from Peak XV, its regulatory filing accessed from the Registrar of Companies (RoC) shows. The company plans to utilise the funds for business expansion and to support its growth plans, according to the filing. As per Entrackr’s estimates, its valuation stood at $410 million (Rs 3,487 crore) in the new tranche (post-allotment), a 22% increase from its C1 tranche. Founded by Naitik Nayyar and Akshat Wani, Truemeds helps consumers discover cost-effective alternative brands for prescribed medicines by analyzing the prescriptions they upload. It partners with certified pharmacies to deliver medicines at discounted prices, aiming to make healthcare more affordable and accessible. According to startup data intelligence platform TheKredible, the firm has raised over $90 million to date. Following the latest allotment, Peak XV holds a 5% stake in the company. Westbridge is the largest shareholder in Truemeds followed by Info Edge which owns 21.87% stake. Co-founders Naitik Nayyar and Akshat Wani both collectively retain 21.3%. Truemeds doubled its revenue to Rs 315 crore in FY24, while its losses narrowed by 9% to Rs 61 crore during the same period. The Mumbai-based firm competes with telehealth platforms like PharmEasy, which recorded Rs 5,664 crore in revenue in FY24, and Tata 1mg, which posted Rs 1,964 crore.

1

Related News

Exclusive: The Whole Truth kicks off Series C with 3.6X valuation surge

EntrackrEntrackr · 7m ago
Exclusive: The Whole Truth kicks off Series C with 3.6X valuation surge
Medial

Exclusive: The Whole Truth kicks off Series C with 3.6X valuation surge Clean-label health food brand The Whole Truth is raising Rs 133.3 crore (approximately $15.8 million) in a series C round led by Sofina Ventures, with the participation of Peak XV and Matrix Partners. The board at The Whole Truth has passed a special resolution to issue 45,097 Series C preference shares at an issue price of Rs 29,556.5 each to raise Rs 133.3 crore or $15.8 million, its regulatory filing accessed from the Registrar of Companies (RoC) shows. Sofina Ventures is leading the Series C round with an investment of Rs 65.8 crore, while Peak XV and Matrix Partners will contribute Rs 25 crore and Rs 29.5 crore, respectively. Sauce Continued Fund will also participate with an investment of Rs 13 crore. The fresh funds will be used to meet financial requirements and support business expansion. According to Entrackr’s estimates, the Mumbai-based company will have a post-allotment valuation of approximately Rs 2,135 crore ($254 million). This marks a 3.6X increase in valuation compared to its previous Series B round, which closed at $70 million. According to the filings, after the fresh funding round, Peak XV will hold 21.14% of the firm, while Matrix Partners will own 21.4%. Sofina Ventures and Sauce Continuity will hold 3.08% and 3.77%, respectively. The Whole Truth was reportedly in discussions to raise $25 million in a new funding round. The company has secured $15.8 million so far and may raise additional funds as the round progresses. The Whole Truth offers a range of products, including protein bars, peanut butter, dark chocolates, energy bars, immunity balls, and muesli. The company provides subscription options and claims that 80-85% of its sales come from its website, with the remaining revenue generated through partnerships. The Whole Truth recorded an 81% year-on-year growth, with revenue rising to Rs 65.3 crore in FY24 from Rs 35.96 crore in FY23. The company reduced its losses by 33% during the same period.

Truemeds to raise $44 Mn led by Accel India

EntrackrEntrackr · 6m ago
Truemeds to raise $44 Mn led by Accel India
Medial

Telehealth platform Truemeds is raising Rs 375.2 crore or (approximately $44 million) in its Series C round led by Accel India and with the participation of WestBridge and Info Edge. The board at Telehealth platform Truemeds has passed a special resolution to issue 1 equity and 49,300 Series C preference shares at an issue price of Rs 76,110 each to raise the aforementioned sum, its regulatory filing accessed from the Registrar of Companies (RoC) shows. Accel India will invest Rs 285.4 crore, while WestBridge, through its investment vehicles Konark and MMPL Trust, will contribute Rs 68.49 crore. Info Edge will also join the round with Rs 21.31 crore. The company will use these proceeds to advance the business and facilitate the planned growth, as per filings. According to Entrackr’s estimates, the company will be valued at around $340 million (post-money). With the new funding, Accel India will hold approximately 10% of the company, while WestBridge and Info Edge will own 28.64% and 23.02%, respectively. Co-founders Akshat Nayyar and Kunal Wani will collectively retain a 22.43% stake in their personal capacity. Founded by Nayyar and Wani, Truemeds lets consumers find medicines of alternate brands with the help of prescriptions uploaded by them. Truemeds recorded an impressive two-fold growth in its revenue to Rs 315 crore during the fiscal year ended March 2024. Efficient cost management and scaling efforts also contributed to a 9% reduction in losses, bringing them down to Rs 61 crore during the same period. Awareness of generic medicines has been rising fast in India, thanks to government-backed efforts to provide cheaper meds at both state and central levels. While that has created a market for users looking beyond the prescribed options, it also brings with it the biggest challenge for Truemeds. Truly successful government efforts will undermine growth in quite a few of the high-volume categories. However, with government efforts focused on select, high-usage molecules, it leaves enough potential for firms like Truemeds to capitalize on the new awareness for options. That seems to be the thesis of the latest funding at least. Be it vitamins and supplements, or even Homeopathic meds, the firm has built up a wide selection on offer for users seeking cheaper options here. Competition remains intense, however, both from government-backed pharmacies or private pharmacies that have also latched on to the new reality of a changing market.

Mosaic Wellness raises $20 Mn at $400 Mn valuation

EntrackrEntrackr · 5m ago
Mosaic Wellness raises $20 Mn at $400 Mn valuation
Medial

Exclusive: Mosaic Wellness raises $20 Mn at $400 Mn valuation Mosaic Wellness, the parent firm of Man Matters, Boywise, and Little Joys, has raised Rs 175 crore (approximately $20 million) from Think Investment in a new round. The board at Mosaic Wellness has passed a special resolution to issue 16,279 compulsory convertible preference shares at an issue price of Rs 1,07,500 each to raise Rs 175 crore or $20 million, its regulatory filing accessed from the Registrar of Companies (RoC) shows. The filings further noted that the company plans to utilize the fresh capital for growth, expansion, and general corporate purposes. According to Entrackr estimates, the company has been valued at around $400 million post-allotment. Following the fresh proceeds, Think Investment will hold 5.04% of the company. Founded in 2020 by Revant Bhate and Dhyanesh Shah, Mosaic Wellness is a digital-first consumer health platform that runs three separate brands for men, women, and kids. Its flagship brand ManMatters offers solutions across derma, sexual health, hygiene, and nutrition. Mosaic Wellness has raised over $65 million to date, including its $24 million Series A led by Peak XV along with existing investors Elevation Capital and Matrix Partners India in 2021. As per the startup data intelligence platform TheKredible, Elevation Capital is the largest external stakeholder, followed by Peak XV and Matrix Partners. The company has recorded a 61.7% year-on-year growth to Rs 333 crore during the fiscal year ended March 2024, compared to Rs 206 crore in FY23. Moreover, the firm managed to control its losses by 37.1% to Rs 39 crore in the same period.

Download the medial app to read full posts, comements and news.